BCYC BICYCLE THERAPEUTICS plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCYC

Price (delayed)

$4.28

Market cap

$298.79M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.15

Enterprise value

-$246.81M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 30

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short ...

Highlights
BICYCLE THERAPEUTICS's gross profit has surged by 147% YoY but it has decreased by 13% QoQ
BCYC's revenue has soared by 147% YoY but it is down by 13% QoQ
BCYC's equity is down by 25% year-on-year and by 9% since the previous quarter
BCYC's net income is down by 8% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.bicycletherapeutics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of BCYC

BCYC stock price

How has the BICYCLE THERAPEUTICS stock price performed over time
Intraday
1.9%
1 week
-8.35%
1 month
-13.36%
1 year
-49.41%
YTD
-39.55%
QTD
-7.76%

Financial performance

How have BICYCLE THERAPEUTICS's revenue and profit performed over time
Revenue
$63.5M
Gross profit
$63.5M
Operating income
-$242.34M
Net income
-$219.03M
Gross margin
100%
Net margin
-345%
BICYCLE THERAPEUTICS's gross profit has surged by 147% YoY but it has decreased by 13% QoQ
BCYC's revenue has soared by 147% YoY but it is down by 13% QoQ
The operating margin has soared by 60% YoY but it has contracted by 12% from the previous quarter
BCYC's net margin has soared by 56% year-on-year but it is down by 14% since the previous quarter

Price vs fundamentals

How does BCYC's price correlate with its fundamentals

Growth

What is BICYCLE THERAPEUTICS's growth rate over time

Valuation

What is BICYCLE THERAPEUTICS stock price valuation
P/E
N/A
P/B
0.54
P/S
4.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.89
The stock's P/B is 78% below its 5-year quarterly average of 2.4 and 24% below its last 4 quarters average of 0.7
BCYC's equity is down by 25% year-on-year and by 9% since the previous quarter
BCYC's revenue has soared by 147% YoY but it is down by 13% QoQ
The P/S is 89% less than the 5-year quarterly average of 42.1 and 67% less than the last 4 quarters average of 13.9

Efficiency

How efficient is BICYCLE THERAPEUTICS business performance
BICYCLE THERAPEUTICS's ROS has soared by 58% YoY but it has decreased by 14% from the previous quarter
The ROE has contracted by 42% YoY and by 8% from the previous quarter
The ROA has contracted by 41% YoY and by 8% from the previous quarter
The company's return on invested capital rose by 12% QoQ and by 5% YoY

Dividends

What is BCYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCYC.

Financial health

How did BICYCLE THERAPEUTICS financials performed over time
The total liabilities has contracted by 32% YoY and by 9% from the previous quarter
BICYCLE THERAPEUTICS's total assets has decreased by 26% YoY and by 9% from the previous quarter
BCYC's debt is 97% smaller than its equity
BICYCLE THERAPEUTICS's debt to equity has soared by 50% from the previous quarter
BCYC's equity is down by 25% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.